Logo image of YTEN

YIELD10 BIOSCIENCE INC (YTEN) Stock Fundamental Analysis

NASDAQ:YTEN - Nasdaq - US98585K8541 - Common Stock - Currency: USD

2.88  -2.38 (-45.25%)

After market: 2.89 +0.01 (+0.35%)

Fundamental Rating

1

Overall YTEN gets a fundamental rating of 1 out of 10. We evaluated YTEN against 560 industry peers in the Biotechnology industry. Both the profitability and financial health of YTEN have multiple concerns. While showing a medium growth rate, YTEN is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

In the past year YTEN has reported negative net income.
YTEN had a negative operating cash flow in the past year.
In the past 5 years YTEN always reported negative net income.
YTEN had a negative operating cash flow in each of the past 5 years.
YTEN Yearly Net Income VS EBIT VS OCF VS FCFYTEN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -5M -10M -15M -20M

1.2 Ratios

Looking at the Return On Assets, with a value of -370.00%, YTEN is doing worse than 96.74% of the companies in the same industry.
Industry RankSector Rank
ROA -370%
ROE N/A
ROIC N/A
ROA(3y)-197.19%
ROA(5y)-147.92%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
YTEN Yearly ROA, ROE, ROICYTEN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 500 1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for YTEN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
YTEN Yearly Profit, Operating, Gross MarginsYTEN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -5K -10K -15K -20K

0

2. Health

2.1 Basic Checks

YTEN does not have a ROIC to compare to the WACC, probably because it is not profitable.
YTEN has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, YTEN has more shares outstanding
YTEN has a worse debt/assets ratio than last year.
YTEN Yearly Shares OutstandingYTEN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 1M 2M 3M 4M
YTEN Yearly Total Debt VS Total AssetsYTEN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M

2.2 Solvency

YTEN has an Altman-Z score of -157.47. This is a bad value and indicates that YTEN is not financially healthy and even has some risk of bankruptcy.
YTEN has a Altman-Z score of -157.47. This is amonst the worse of the industry: YTEN underperforms 98.46% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -157.47
ROIC/WACCN/A
WACC9.13%
YTEN Yearly LT Debt VS Equity VS FCFYTEN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10M -10M -20M

2.3 Liquidity

YTEN has a Current Ratio of 0.29. This is a bad value and indicates that YTEN is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of YTEN (0.29) is worse than 96.57% of its industry peers.
A Quick Ratio of 0.29 indicates that YTEN may have some problems paying its short term obligations.
With a Quick ratio value of 0.29, YTEN is not doing good in the industry: 96.23% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.29
Quick Ratio 0.29
YTEN Yearly Current Assets VS Current LiabilitesYTEN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M

4

3. Growth

3.1 Past

YTEN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -1075.36%.
YTEN shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -86.67%.
Measured over the past years, YTEN shows a very negative growth in Revenue. The Revenue has been decreasing by -36.03% on average per year.
EPS 1Y (TTM)-1075.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-867.16%
Revenue 1Y (TTM)-86.67%
Revenue growth 3Y-57.83%
Revenue growth 5Y-36.03%
Sales Q2Q%-100%

3.2 Future

The Earnings Per Share is expected to grow by 14.95% on average over the next years. This is quite good.
The Revenue is expected to grow by 288.42% on average over the next years. This is a very strong growth
EPS Next Y97.63%
EPS Next 2Y40.47%
EPS Next 3Y25.9%
EPS Next 5Y14.95%
Revenue Next Year2712.5%
Revenue Next 2Y607.11%
Revenue Next 3Y594.08%
Revenue Next 5Y288.42%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
YTEN Yearly Revenue VS EstimatesYTEN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 20M 40M 60M 80M 100M
YTEN Yearly EPS VS EstimatesYTEN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -500 -1K -1.5K

1

4. Valuation

4.1 Price/Earnings Ratio

YTEN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year YTEN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
YTEN Price Earnings VS Forward Price EarningsYTEN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
YTEN Per share dataYTEN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20 -30

4.3 Compensation for Growth

A more expensive valuation may be justified as YTEN's earnings are expected to grow with 25.90% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.47%
EPS Next 3Y25.9%

0

5. Dividend

5.1 Amount

No dividends for YTEN!.
Industry RankSector Rank
Dividend Yield N/A

YIELD10 BIOSCIENCE INC

NASDAQ:YTEN (5/15/2024, 8:18:42 PM)

After market: 2.89 +0.01 (+0.35%)

2.88

-2.38 (-45.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2024-05-08/amc
Earnings (Next)08-12 2024-08-12/amc
Inst Owners1.81%
Inst Owner Change0%
Ins Owners1.67%
Ins Owner Change0%
Market Cap44.35M
Analysts45.71
Price Target12.24 (325%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)5.51%
Min EPS beat(2)-2.19%
Max EPS beat(2)13.21%
EPS beat(4)1
Avg EPS beat(4)-5.53%
Min EPS beat(4)-17.65%
Max EPS beat(4)13.21%
EPS beat(8)2
Avg EPS beat(8)-4.93%
EPS beat(12)4
Avg EPS beat(12)-2.47%
EPS beat(16)6
Avg EPS beat(16)-1.17%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2300%
PT rev (3m)433.33%
EPS NQ rev (1m)-2300%
EPS NQ rev (3m)-738.09%
EPS NY rev (1m)0%
EPS NY rev (3m)19.4%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)101.49%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 739.2
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-32.44
EYN/A
EPS(NY)-0.77
Fwd EYN/A
FCF(TTM)-0.66
FCFYN/A
OCF(TTM)-0.65
OCFYN/A
SpS0
BVpS-0.16
TBVpS-0.16
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -370%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-197.19%
ROA(5y)-147.92%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 15.86%
Cap/Sales 76.67%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.29
Quick Ratio 0.29
Altman-Z -157.47
F-Score2
WACC9.13%
ROIC/WACCN/A
Cap/Depr(3y)53.31%
Cap/Depr(5y)46.87%
Cap/Sales(3y)47.05%
Cap/Sales(5y)31.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1075.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-867.16%
EPS Next Y97.63%
EPS Next 2Y40.47%
EPS Next 3Y25.9%
EPS Next 5Y14.95%
Revenue 1Y (TTM)-86.67%
Revenue growth 3Y-57.83%
Revenue growth 5Y-36.03%
Sales Q2Q%-100%
Revenue Next Year2712.5%
Revenue Next 2Y607.11%
Revenue Next 3Y594.08%
Revenue Next 5Y288.42%
EBIT growth 1Y-7.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year23.31%
EBIT Next 3Y16.98%
EBIT Next 5Y24.41%
FCF growth 1Y12.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y11.68%
OCF growth 3YN/A
OCF growth 5YN/A